10.1007/s40204-021-00154-7

Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies

Show Details XML
  • Krishna Yadav1,
  • Akanksha Soni1,
  • Deependra Singh1,
  • Manju Rawat Singh*1,
  1. University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, 492010, IN

Published in Issue 2021-03-18

How to Cite

Yadav, K., Soni, A., Singh, D., & Singh, M. R. (2021). Polymers in topical delivery of anti-psoriatic medications and other topical agents in overcoming the barriers of conventional treatment strategies. Progress in Biomaterials, 10(1 (March 2021). https://doi.org/10.1007/s40204-021-00154-7
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract In recent decades, topical treatments to dermal disorders have shown ineffectiveness in delivering the medication at a particular location without a suitable drug carrier. Psoriasis treatment is hindered because of the ineffective delivery and efficacy of conventional pharmaceutical treatment. In conventional medication formulation approach, it is difficult to breach the transdermal layer of a skin membrane for topical drugs, i.e. cyclosporine, methotrexate. This problem is further complicated by extreme disease-associated conditions such as hyperkeratosis and irritation. Intending to assure better drug delivery carriers, this review emphasizes the therapeutic efficacy of polymers and their potential to deliver the drug into the deeper layer of the skin membrane. The polymers are essential in structural and physiochemical perspectives as it works as a carrier for the medication. A vast variety of delivery carriers is available nowadays but their applicability in such dermal cases like psoriasis is still lacking due to less knowledge on an appropriate polymer. The current investigation of suitable polymer would assist in brushing our expertise to optimize the advantages of a wide spectrum of polymers to fulfill the topical targeting of psoriasis.

Keywords

  • Psoriasis,
  • Hyperkeratosis,
  • Inflammation,
  • Polymeric carrier,
  • Immune-mediated skin disorder

References

  1. Abbina S, Parambath A (2018) 14 -PEGylation and its alternatives: a summary. In: Parambath A (ed) Engineering of Biomaterials for Drug Delivery Systems. Woodhead Pub, pp 363–376
  2. Abdelbary and Aboughaly (2015) Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study (pp. 235-243) https://doi.org/10.1016/j.ijpharm.2015.03.020
  3. Abdelgawad et al. (2016) Topical and systemic dermal carriers for psoriasis (pp. 4-9)
  4. Abdelgawad et al. (2017) Phospholipid membrane tubulation using ceramide doping “Cerosomes”: characterization and clinical application in psoriasis treatment (pp. 258-268) https://doi.org/10.1016/j.ejps.2017.02.030
  5. Abed SN, Deb PK, Surchi HS, et al (2019) Nanocarriers in Different Preclinical and Clinical Stages. Elsevier Inc
  6. Acharya U (2017) Formulation and evaluation of nano emulsion based system for transdermal delivery of antipsoriatic drug. World J Pharm Pharm Sci.
  7. https://doi.org/10.20959/wjpps20177-9430
  8. Agrawal et al. (2013) Hyperbranched dendritic nano-carriers for topical delivery of dithranol (pp. 497-506) https://doi.org/10.3109/1061186X.2013.771778
  9. Alama et al. (2019) Mechanistic studies on the absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs in rats https://doi.org/10.3390/pharmaceutics11040170
  10. Alvarez-Figueroa and Blanco-Méndez (2001) Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions (pp. 57-65) https://doi.org/10.1016/S0378-5173(00)00674-8
  11. Anselmo and Mitragotri (2014) An overview of clinical and commercial impact of drug delivery systems (pp. 15-28) https://doi.org/10.1016/j.jconrel.2014.03.053
  12. Avasatthi et al. (2016) A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation (pp. 554-562) https://doi.org/10.3109/10837450.2015.1026605
  13. Badıllı et al. (2011) Microparticulate based topical delivery system of clobetasol propionate (pp. 949-957) https://doi.org/10.1208/s12249-011-9661-7
  14. Bakshi et al. (2020) Treatment of psoriasis: a comprehensive review of entire therapies https://doi.org/10.2174/1574886315666200128095958
  15. Batheja et al. (2011) Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies (pp. 159-167) https://doi.org/10.1016/j.jconrel.2010.10.005
  16. Beber et al. (2016) Cationic polymeric nanocapsules as a strategy to target dexamethasone to viable epidermis: skin penetration and permeation studies (pp. 1331-1338) https://doi.org/10.1166/jnn.2016.11670
  17. Bennet and Kim (2013) A transdermal delivery system to enhance quercetin nanoparticle permeability (pp. 185-209) https://doi.org/10.1163/156856212X630258
  18. Borowska et al. (2012) Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene–in vivo study (pp. 280-283) https://doi.org/10.1016/j.ijpharm.2012.01.041
  19. Cai et al. (2016) Investigating the ability of nanoparticle-loaded hydroxypropyl methylcellulose and xanthan gum gels to enhance drug penetration into the skin (pp. 302-308) https://doi.org/10.1016/j.ijpharm.2016.08.055
  20. Calzoni et al. (2019) Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies https://doi.org/10.3390/jfb10010004
  21. Chan et al. (2018) Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment (pp. 111-119) https://doi.org/10.1177/2040622318759282
  22. Chandrashekara (2012) The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review (pp. 665-671) https://doi.org/10.4103/0253-7613.103235
  23. Chenthamara et al. (2019) Therapeutic efficacy of nanoparticles and routes of administration https://doi.org/10.1186/s40824-019-0166-x
  24. Collado-González et al. (2017) Chitosan as stabilizing agent for negatively charged nanoparticles (pp. 63-70) https://doi.org/10.1016/J.CARBPOL.2016.12.043
  25. Damiani et al. (2019) Nanodermatology-based solutions for psoriasis: state-of-the art and future prospects https://doi.org/10.1111/dth.13113
  26. Danhier et al. (2012) PLGA-based nanoparticles: an overview of biomedical applications (pp. 505-522) https://doi.org/10.1016/j.jconrel.2012.01.043
  27. Dayal et al. (2018) Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis (pp. 385-390) https://doi.org/10.1590/abd1806-4841.20186723
  28. De et al. (2017) In situ delivery of corticosteroids for treatment of oral diseases (pp. 899-914) https://doi.org/10.4155/tde-2017-0055
  29. de Britto and Campana-Filho (2007) Kinetics of the thermal degradation of chitosan (pp. 73-82) https://doi.org/10.1016/j.tca.2007.09.008
  30. de Britto et al. (2011) Quaternary salts of chitosan: history, antimicrobial features, and prospects (pp. 1-12) https://doi.org/10.1155/2011/312539
  31. Desai et al. (2013) Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo (pp. 51-63) https://doi.org/10.1016/j.jconrel.2013.04.021
  32. Dhaneshwar et al. (2006) Dextran: a promising macromolecular drug carrier (pp. 705-714) https://doi.org/10.4103/0250-474X.31000
  33. Di Meglio et al. (2014) Psoriasis (pp. a015354-a015354) https://doi.org/10.1101/cshperspect.a015354
  34. Dodane et al. (1999) Effect of chitosan on epithelial permeability and structure (pp. 21-32) https://doi.org/10.1016/S0378-5173(99)00030-7
  35. Domínguez-delgado CL, Rodríguez-cruz IM, Fuentes-prado E, et al (2014) Drug Carrier Systems Using Chitosan for Non Parenteral Routes. Pharmacol Ther 273–275
  36. Elder JT, Bruce AT, Gudjonsson JE, et al (2010) Molecular Dissection of Psoriasis : Integrating Genetics and Biology.
  37. https://doi.org/10.1038/jid.2009.319
  38. Essaghraoui et al. (2019) Improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles https://doi.org/10.3390/nano9091204
  39. Fan et al. (2016) Treating psoriasis by targeting its susceptibility gene (pp. 47-54) https://doi.org/10.1016/j.clim.2016.03.009
  40. Farajzadeh et al. (2018) Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells (pp. 917-925) https://doi.org/10.1080/21691401.2017.1347879
  41. Ferreira et al. (2016) Methotrexate loaded lipid nanoparticles for topical management of skin-related diseases: design, characterization and skin permeation potential (pp. 14-21) https://doi.org/10.1016/j.ijpharm.2016.08.008
  42. Ferreira et al. (2017) Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: a targeted approach for psoriasis management (pp. 23-29) https://doi.org/10.1016/j.colsurfb.2017.07.080
  43. Gabriel et al. (2016) Improved topical delivery of tacrolimus: a novel composite hydrogel formulation for the treatment of psoriasis (pp. 16-24) https://doi.org/10.1016/j.jconrel.2016.09.007
  44. Gaikwad et al. (2012) Effect of carbopol 934 and 940 on fluconazole release from topical gel formulation: a factorial approach (pp. 487-493) https://doi.org/10.33786/JCPR.2012.v02i02.004
  45. Ghannoum et al. (2015) Ability of hydroxypropyl Chitosan nail lacquer to protect against dermatophyte nail infection (pp. 1844-1848) https://doi.org/10.1128/AAC.04842-14
  46. Goel et al. (2009) Anti-inflammatory activity of nanogel formulation of 3-acetyl-11-keto- β-boswellic acid (pp. 311-318)
  47. Gong et al. (2012) Polymeric micelles drug delivery system in oncology (pp. 312-323) https://doi.org/10.1016/j.jconrel.2011.12.012
  48. Gordon et al. (2016) Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis (pp. 345-356) https://doi.org/10.1056/NEJMoa1512711
  49. Gul et al. (2018) Rutin and rutin-conjugated gold nanoparticles ameliorate collagen-induced arthritis in rats through inhibition of NF-κB and iNOS activation (pp. 310-317) https://doi.org/10.1016/j.intimp.2018.04.017
  50. Gupta et al. (2013) Nanocarriers and nanoparticles for skin care and dermatological treatments (pp. 267-272) https://doi.org/10.4103/2229-5178.120635
  51. Hoffman et al. (2016) Current challenges and emerging drug delivery strategies for the treatment of psoriasis (pp. 1461-1473) https://doi.org/10.1080/17425247.2016.1188801
  52. Huang and Huang (2018) Application of dextran as nanoscale drug carriers (pp. 3149-3158) https://doi.org/10.2217/nnm-2018-0331
  53. Huang and Huang (2019) The dextrans as vehicles for gene and drug delivery (pp. 1659-1667) https://doi.org/10.4155/fmc-2018-0586
  54. Hussain et al. (2014) Elastic liposome-based gel for topical delivery of 5-fluorouracil: in vitro and in vivo investigation (pp. 1-15) https://doi.org/10.3109/10717544.2014.976891
  55. Hussain et al. (2014) Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation (pp. 1-16)
  56. Irey et al. (2019) JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors (pp. 12442-12451) https://doi.org/10.1073/pnas.1816410116
  57. Ishihara et al. (2005) Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile (pp. 68-76) https://doi.org/10.1016/j.jconrel.2005.02.026
  58. Jackson et al. (2013) Nanotechnological advances in cutaneous medicine https://doi.org/10.1155/2013/808234
  59. Jain and Thareja (2019) In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery (pp. 524-539) https://doi.org/10.1080/21691401.2018.1561457
  60. Jain et al. (2016) Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis (pp. 132-145) https://doi.org/10.1016/j.jconrel.2016.10.004
  61. Jijie et al. (2017) Nanomaterials for transdermal drug delivery: beyond the state of the art of liposomal structures https://doi.org/10.1039/C7TB02529G
  62. Jin et al. (2015) Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis (pp. 405-409) https://doi.org/10.1016/j.colsurfb.2015.02.038
  63. Jose et al. (2018) Polymeric lipid hybrid nanoparticles: properties and therapeutic applications (pp. 555-588) https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024751
  64. Kamoun et al. (2017) A review on polymeric hydrogel membranes for wound dressing applications: PVA-based hydrogel dressings (pp. 217-233) https://doi.org/10.1016/j.jare.2017.01.005
  65. Kapoor DN, Dhawan S (2013) Biocompatible Nanomaterials for Targeted and Controlled Delivery of Biomacromolecules. ASME
  66. Kapoor et al. (2015) PLGA: A unique polymer for drug delivery (pp. 41-58) https://doi.org/10.4155/tde.14.91
  67. Katare et al. (2010) Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors https://doi.org/10.4103/0378-6323.72451
  68. Kaur et al. (2017) Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis (pp. 1473-1482) https://doi.org/10.1016/j.nano.2017.02.009
  69. Keijsers et al. (2014) In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17 (pp. 1276-1284) https://doi.org/10.1038/jid.2013.526
  70. Khadka et al. (2014) Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability (pp. 304-316) https://doi.org/10.1016/j.ajps.2014.05.005
  71. Kilfoyle et al. (2012) Development of paclitaxel-TyroSpheres for topical skin treatment (pp. 18-24) https://doi.org/10.1016/j.jconrel.2012.06.021
  72. Kim et al. (2003) Rheological properties and microstructures of carbopol gel network system (pp. 614-623) https://doi.org/10.1007/s00396-002-0808-7
  73. Kim et al. (2020) Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model https://doi.org/10.1186/s12951-020-00693-4
  74. Knudsen et al. (2012) Calcipotriol delivery into the skin with PEGylated liposomes (pp. 532-539) https://doi.org/10.1016/j.ejpb.2012.04.005
  75. Kumari et al. (2010) Biodegradable polymeric nanoparticles based drug delivery systems (pp. 1-18) https://doi.org/10.1016/j.colsurfb.2009.09.001
  76. Kumirska et al. (2011) Biomedical activity of chitin/chitosan based materials- influence of physicochemical properties apart from molecular weight and degree of N-Acetylation (pp. 1875-1901) https://doi.org/10.3390/polym3041875
  77. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T (2017) The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017
  78. Lakshmi et al. (2007) Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies (pp. 157-161) https://doi.org/10.4103/0378-6323.32709
  79. Lapteva et al. (2014) Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis (pp. 2989-3001) https://doi.org/10.1021/mp400639e
  80. Li et al. (2001) PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats (pp. 203-211) https://doi.org/10.1016/S0168-3659(01)00218-8
  81. Lima et al. (2020) Understanding the lipid and protein corona formation on different sized polymeric nanoparticles https://doi.org/10.1038/s41598-020-57943-6
  82. Lombardo et al. (2019) Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine (pp. 1-26) https://doi.org/10.1155/2019/3702518
  83. Lotfi-Attari et al. (2017) Co-delivery of curcumin and chrysin by polymeric nanoparticles inhibit synergistically growth and hTERT gene expression in human colorectal cancer cells (pp. 1290-1299) https://doi.org/10.1080/01635581.2017.1367932
  84. Lou et al. (2019) Dextran-based mycophenolic acid nanoparticle ameliorates imiquimod-induced psoriasis-like skin inflammation https://doi.org/10.1016/j.jid.2019.03.137
  85. Ludbrook et al. (2016) Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study (pp. 985-995) https://doi.org/10.1111/bjd.14399
  86. Makadia and Siegel (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier (pp. 1377-1397) https://doi.org/10.3390/polym3031377
  87. Mao et al. (2017) Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model (pp. 704-714) https://doi.org/10.1016/j.colsurfb.2017.10.029
  88. Marchiori et al. (2010) Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study (pp. 962-971) https://doi.org/10.3109/03639041003598960
  89. Mathew et al. (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease https://doi.org/10.1371/journal.pone.0032616
  90. Maurya et al. (2019) Strategic use of nanotechnology in drug targeting and its consequences on human health: a focused review (pp. 38-54) https://doi.org/10.1556/1646.11.2019.04
  91. Md et al. (2018) Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders (pp. 295-310) https://doi.org/10.1016/j.jddst.2017.09.022
  92. Mease PJ, McInnes IB, Reich K, et al (2017) FRI0511 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses
  93. Milton Harris and Chess (2003) Effect of pegylation on pharmaceuticals (pp. 214-221) https://doi.org/10.1038/nrd1033
  94. Mirtič et al. (2017) Development of medicated foams that combine incompatible hydrophilic and lipophilic drugs for psoriasis treatment (pp. 65-76) https://doi.org/10.1016/j.ijpharm.2017.03.061
  95. Morganti et al. (2001) Percutaneous absorption and delivery systems (pp. 489-501) https://doi.org/10.1016/S0738-081X(01)00183-3
  96. Mourya and Inamdar (2009) Trimethyl chitosan and its applications in drug delivery (pp. 1057-1079) https://doi.org/10.1007/s10856-008-3659-z
  97. Naga et al. (2014) Calcipotriol delivery into the skin as emulgel for effective permeation (pp. 591-599) https://doi.org/10.1016/j.jsps.2014.02.007
  98. Nemati et al. (2017) Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis (pp. 259-268) https://doi.org/10.1016/j.jconrel.2017.10.034
  99. Nguyen and Banga (2018) Electrically and ultrasonically enhanced transdermal delivery of methotrexate https://doi.org/10.3390/pharmaceutics10030117
  100. Ourique et al. (2008) Tretinoin-loaded nanocapsules: preparation, physicochemical characterization, and photostability study (pp. 1-4) https://doi.org/10.1016/j.ijpharm.2007.12.035
  101. Ourique et al. (2011) Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine (pp. 95-101) https://doi.org/10.1016/j.ejpb.2011.03.008
  102. Palmer BC, DeLouise LA (2016) Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules 21
  103. Pandey SK, Haldar C, Patel DK, Maiti P (2013) Biodegradable polymers for potential delivery systems for therapeutics. pp 169–202
  104. Panonnummal and Sabitha (2018) Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model (pp. 245-258) https://doi.org/10.1016/j.ijbiomac.2017.10.112
  105. Papp et al. (2013) Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up (pp. 844-854) https://doi.org/10.1111/bjd.12214
  106. Papp et al. (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study (pp. 841-850) https://doi.org/10.1016/j.jaad.2016.01.013
  107. Paredes and Alarcón (2019) The state of the art of investigational and approved nanomedicine products for nucleic acid delivery https://doi.org/10.1016/B978-0-12-814470-1.00015-0
  108. Patel S, Dwivedi SD, Yadav K, et al (2020) Pathogenesis and Molecular Targets in Treatment of Diabetic Wounds. In: Obesity and Diabetes, J. Faintuc. Springer Nature Switzerland AG 2020, pp 747–758
  109. Pinelli et al. (2020) Coating and functionalization strategies for nanogels and nanoparticles for selective drug delivery https://doi.org/10.3390/gels6010006
  110. Prabaharan and Mano (2005) Chitosan-based particles as controlled drug delivery systems (pp. 41-57) https://doi.org/10.1080/10717540590889781
  111. Pradhan et al. (2013) Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches (pp. 380-395) https://doi.org/10.1016/j.jconrel.2013.05.020
  112. Pradhan et al. (2018) Understanding the prospective of nano-formulations towards the treatment of psoriasis (pp. 447-463) https://doi.org/10.1016/j.biopha.2018.07.156
  113. Pradhan et al. (2020) Statistically optimized calcipotriol fused nanostructured lipid carriers for effectual topical treatment of psoriasis https://doi.org/10.1016/j.jddst.2020.102168
  114. Pradhan et al. (2021) Topical delivery of fluocinolone acetonide integrated NLCs and salicylic acid enriched gel: a potential and synergistic approach in the management of psoriasis https://doi.org/10.1016/j.jddst.2020.102282
  115. Prasad and Chaurasia (2017) Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis (pp. 168-176) https://doi.org/10.1016/j.msec.2017.05.036
  116. Prausnitz MR, Elias PM, Franz TJ, et al (2012) Skin Barrier and Transdermal Drug Delivery. Med Ther 2065–2073
  117. Proniuk and Blanchard (2002) Anhydrous Carbopol polymer gels for the topical delivery of oxygen/water sensitive compounds (pp. 249-255) https://doi.org/10.1081/pdt-120003492
  118. Prosperi et al. (2017) Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases (pp. 61-67) https://doi.org/10.1016/j.smim.2017.08.010
  119. Rahman et al. (2015) Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy (pp. 635-652) https://doi.org/10.1517/17425247.2015.982088
  120. Ramanunny et al. (2020) Treatment strategies against psoriasis: principle, perspectives and practices (pp. 52-73) https://doi.org/10.2174/1567201816666191120120551
  121. Ramezanli et al. (2017) Polymeric nanospheres for topical delivery of vitamin D3 (pp. 196-203) https://doi.org/10.1016/j.ijpharm.2016.10.072
  122. Raza et al. (2013) Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity (pp. 65-72) https://doi.org/10.1016/j.ijpharm.2013.08.019
  123. Ridolfi et al. (2012) Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin (pp. 36-40) https://doi.org/10.1016/j.colsurfb.2011.11.051
  124. Roberts et al. (2017) Topical and cutaneous delivery using nanosystems (pp. 86-105) https://doi.org/10.1016/j.jconrel.2016.12.022
  125. Rønholt and Iversen (2017) Old and new biological therapies for psoriasis https://doi.org/10.3390/ijms18112297
  126. Rosado et al. (2013) Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment (pp. 710-718) https://doi.org/10.3109/10837450.2012.712537
  127. Sala et al. (2018) Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications (pp. 1-17) https://doi.org/10.1016/j.ijpharm.2017.10.046
  128. Saleem et al. (2020) Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis https://doi.org/10.1080/17425247.2020.1758665
  129. Schipper et al. (1999) Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption enhancement (pp. 335-343) https://doi.org/10.1016/s0928-0987(99)00032-9
  130. Şenyiğit et al. (2010) Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin (pp. 368-373) https://doi.org/10.1016/j.jconrel.2009.11.013
  131. Shah et al. (2012) Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs (pp. 1607-1617) https://doi.org/10.1016/j.biomaterials.2011.11.011
  132. Shah et al. (2016) Percutaneous delivery of α -melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis (pp. 537-547) https://doi.org/10.3109/1061186X.2015.1103743
  133. Siepmann (2001) Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC) (pp. 139-157) https://doi.org/10.1016/S0169-409X(01)00112-0
  134. Singh et al. (2017) PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: cellular uptake, cytotoxic and pharmacokinetic evidences (pp. 750-756) https://doi.org/10.1016/j.ijbiomac.2016.11.111
  135. Singka et al. (2010) Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel (pp. 275-281) https://doi.org/10.1016/j.ejpb.2010.06.014
  136. Sivaram et al. (2015) Nanogels for delivery, imaging and therapy (pp. 509-533) https://doi.org/10.1002/wnan.1328
  137. Srisuk et al. (2012) Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment (pp. 426-434) https://doi.org/10.1016/j.ijpharm.2012.01.045
  138. Suk et al. (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery (pp. 28-51) https://doi.org/10.1016/j.addr.2015.09.012
  139. Sumit et al. (2012) Potential of chitosan for nose to brain drug delivery (pp. 47-55)
  140. Sun et al. (2017) Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel (pp. 44-54) https://doi.org/10.1016/J.JCONREL.2017.03.385
  141. Talele et al. (2017) A research article on nanogel as topical promising drug delivery for diclofenac sodium (pp. s580-s587) https://doi.org/10.5530/ijper.51.4s.86
  142. Tanghetti et al. (2019) Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology https://doi.org/10.1080/09546634.2019.1668907
  143. Thanou et al. (2001) Chitosan and its derivatives as intestinal absorption enhancers 50(Suppl 1) (pp. S91-101) https://doi.org/10.1016/s0169-409x(01)00180-6
  144. Tomoda et al. (2012) Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis (pp. 84-89) https://doi.org/10.1016/j.colsurfb.2012.04.002
  145. Tonel et al. (2010) Cutting edge: a critical functional role for IL-23 in psoriasis (pp. 5688-5691) https://doi.org/10.4049/jimmunol.1001538
  146. Urdaneta et al. (2017) A review on golimumab in the treatment of psoriatic arthritis (pp. 871-889) https://doi.org/10.2217/imt-2017-0063
  147. Venditti (2019) Morphologies and functionalities of polymeric nanocarriers as chemical tools for drug delivery: a review (pp. 398-411) https://doi.org/10.1016/j.jksus.2017.10.004
  148. Veronese and Pasut (2005) PEGylation, successful approach to drug delivery (pp. 1451-1458) https://doi.org/10.1016/S1359-6446(05)03575-0
  149. Vlaia L, Coneac G, Olariu I et al (2016) Cellulose-Derivatives-Based Hydrogels as Vehicles for Dermal and Transdermal Drug Delivery. In: Emerging Concepts in Analysis and Applications of Hydrogels. InTech
  150. Vyas et al. (2006) Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon α (pp. 699-707) https://doi.org/10.1080/03639040500528954
  151. Wan et al. (2017) Dual roles of TPGS based microemulsion for tacrolimus: enhancing the percutaneous delivery and anti-psoriatic efficacy (pp. 511-523) https://doi.org/10.1016/j.ijpharm.2017.06.050
  152. Wang L-Y, Jelle M, Yang D-P (2008) Preparations of psoralen-loaded PLGA nanoparticles and its characteristics of penetration across human skin. Chine Pharm J 43:1317+1318–1321
  153. Wang et al. (2009) Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis (pp. 4755-4763) https://doi.org/10.4049/jimmunol.0900521
  154. Wang et al. (2011) Preparation of Tacrolimus loaded micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) (pp. 184-189) https://doi.org/10.1016/j.ijpharm.2011.01.018
  155. Yadav et al. (2018) Protein biomarker for psoriasis: a systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis (pp. 1796-1810) https://doi.org/10.1016/j.ijbiomac.2018.07.021
  156. Yadav K, Pawar J, Singh D, Singh MR (2018a) Promising phytoactives candidates for efficacious treatment of psoriasis and other skin disorders. J Ravishankar Univ (Part-B; Sci 31:10–22
  157. Yadav et al. (2020) Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis https://doi.org/10.1016/j.mehy.2020.110322
  158. Yadav K, Chauhan NS, Saraf S, et al (2020a) Challenges and need of delivery carriers for bioactives and biological agents: an introduction. In: Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. Elsevier, pp 1–36
  159. Yadav K, Singh MR, Rai VK, et al (2020c) Commercial aspects and market potential of novel delivery systems for bioactives and biological agents. In: Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents. Elsevier, pp 595–620
  160. Yang et al. (2015) Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis https://doi.org/10.1186/s13020-015-0060-y
  161. Yu et al. (2018) Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose (pp. 129-142) https://doi.org/10.2147/IJN.S150319
  162. Zhang et al. (2020) The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy https://doi.org/10.1016/j.ajps.2019.10.001
  163. Zhao et al. (2018) Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression (pp. 6307-6321) https://doi.org/10.7150/thno.29746
  164. Zielińska et al. (2020) Nanotoxicology and nanosafety: safety-by-design and testing at a glance https://doi.org/10.3390/ijerph17134657
  165. Zielińska et al. (2020) Polymeric nanoparticles: production, characterization https://doi.org/10.3390/molecules25163731
  166. Zuchi MF, Azevedo P de O, Tanaka AA, et al (2015) Serum levels of 25-hydroxy vitamin D in psoriatic patients. An Bras Dermatol 90:430–432.
  167. https://doi.org/10.1590/abd1806-4841.20153524